Core Viewpoint - The company, He Yu-B (02256), experienced a nearly 7% increase in stock price following the release of its financial results, reflecting positive market sentiment driven by strong revenue and profit growth [1] Financial Performance - For the first half of the year, the company reported revenue of 612 million RMB, representing a year-on-year increase of 23.1% [1] - Adjusted profit for the period was 336 million RMB, up 56.03% year-on-year [1] - Net profit reached 328 million RMB, marking a 58.84% increase compared to the previous year [1] Share Buyback - The company has engaged in share buybacks to boost market confidence and enhance shareholder value, repurchasing a total of 9.545 million shares for 75.3 million HKD in the six months ending June 30, 2025 [1] - In 2024, the company repurchased an additional 22.594 million shares for a total of 68.7 million HKD [1] Research and Development - He Yu-B announced the completion of the first patient dosing in a Phase 1 clinical trial for its new PRMT5*MTA inhibitor, ABSK131, targeting late-stage/metastatic solid tumor patients with MTAP deletion [1] - The company received IND approval from the U.S. FDA for ABSK131 in December 2024 and from the China National Medical Products Administration in March 2025 [1]
港股异动 | 和誉-B(02256)绩后涨近7% 中期纯利同比增长58.8%至3.28亿 公司年内持续回购股份